1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Coherus’s Low List Price Adalimumab Stacking Up PBM And Pharmacy Partnerships

Analysts Still Confident In Humira’s Market Share Despite Increasing Competition

 
• By Chloe Kent

Coherus has made deals with numerous pharmacy benefit managers and pharmacies to bring its low list price Yusimry adalimumab biosimilar to patients, as analysts continue to back Humira originator AbbVie as market leader. 

Yusimry pen and packaging
Two PBMs have agreed to supply Yusimry through the Mark Cuban Cost Plus Drug Company • Source: Coherus Biosciences

Coherus Biosciences has made a number of distribution deals to bring its Humira (adalimumab) biosimilar Yusimry (adalimumab-aqvh) to patients, as a second pharmacy benefit manager steps up to offer the drug to its members through Mark Cuban Cost Plus Drug Company. The biosimilar developer has also struck a national distribution agreement for Yusimry through specialty pharmacy Superior Biologics.

PBMs SmithRx and RxPreferred are now both offering Yusimry through Mark Cuban Cost Plus Drug Company, an online pharmacy launched by eponymous celebrity investor Mark Cuban in 2020. Both are offering the drug for $569.27, plus shipping and dispensing fees, a substantial discount to the price of Humira at $6,922 a carton

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

Amgen Locked Out Of Canadian Eculizumab Market Until 2027

 
• By Dean Rudge

Rejecting Amgen’s challenges on the grounds of anticipation and obviousness, Canada’s Federal Court has issued an injunction against the biosimilars firm until patent expiry in March 2027.

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

More from Products

‘We Can’t Keep Going On Like This’ – Biosimilars Forum’s Reed Calls For Urgent Changes In US

 
• By Dave Wallace

As the US biosimilars market moves into its second decade, urgent changes are needed at the FDA if biosimilars are to meet their full potential, according to Biosimilars Forum chief executive Julie Reed.

Biocon Biologics Plans To Slow Down After Five Planned Near-Term Biosimilar Launches

 
• By Urtė Fultinavičiūtė

With a lineup of five high-value biosimilars in the wings, Biocon Biologics may be more selective going forward and plans to take a one product per year approach.

Biocon Eyes Fundraising Round Amid Discussions On Merger With Biosimilars Branch

 
• By Urtė Fultinavičiūtė

As financial volatility continues in the industry, Biocon’s board is considering merging its two off-patent drug businesses.